custirsen 890056-27-6
Custirsen is an experimental drug that is designed to block the production of clusterin, a cell-survival protein that is over-produced in several malignancies and in response to many cancer treatments. Clusterin expression can be associated with treatment resistance and has been linked to faster rates of cancer progression and shorter survival duration.
Clinical Trial Results Custirsen has been administered to nearly 300 patients with various types of cancer in Phase 1 and Phase 2 clinical trials. A broad range of preclinical studies show that custirsen decreases clusterin levels and sensitizes tumor cells to standard chemotherapeutic drugs. Custirsen’s ability to enhance the effects of standard therapies has been evaluated in five Phase 2 clinical trials. The Phase 2 results in prostate cancer suggest there may be an overall survival benefit as well as an improvement in durable pain palliation in prostate cancer. Phase 2 results in lung cancer suggest survival outcomes compared favorably with previously published data of similar regimens.
